AstraZeneca Pharma IndiaNSE:ASTRAZEN +0.83%94 Return-on-Tangible-Equity is 20.57% as of Mar. 2026, which is 8% above its 10-year median of 18.97. GuruFocus rates NSE:ASTRAZEN with a GF Score™ of 94/100 and a GF Value™ of ₹10,925.42 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 897 Drug Manufacturers companies, AstraZeneca Pharma India ranks better than 81.83% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. AstraZeneca Pharma India's annualized net income for the quarter that ended in Mar. 2026 was ₹1,795 Mil. AstraZeneca Pharma India's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹8,728 Mil. Therefore, AstraZeneca Pharma India's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 20.57%.
The historical rank and industry rank for AstraZeneca Pharma India's Return-on-Tangible-Equity or its related term are showing as below:
NSE:ASTRAZEN'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 9.41 Med: 18.97 Max: 24.88
Current: 23.04
During the past 13 years, AstraZeneca Pharma India's highest Return-on-Tangible-Equity was 24.88%. The lowest was 9.41%. And the median was 18.97%.
NSE:ASTRAZEN's Return-on-Tangible-Equity is ranked better than 81.83% of 897
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs NSE:ASTRAZEN: 23.04
AstraZeneca Pharma India (NSE:ASTRAZEN) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
AstraZeneca Pharma India Return-on-Tangible-Equity Related Terms
AstraZeneca Pharma India Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for AstraZeneca Pharma India's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AstraZeneca Pharma India Return-on-Tangible-Equity Chart
NSE:ASTRAZEN vs ZTS, UTHR: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, AstraZeneca Pharma India's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AstraZeneca Pharma India Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AstraZeneca Pharma India's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where AstraZeneca Pharma India's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 20.57% mean?
AstraZeneca Pharma India (NSE:ASTRAZEN) has a Return-on-Tangible-Equity of 20.57% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on AstraZeneca Pharma India and its competitors. This is near median its historical median of 18.97. Over the past decade, AstraZeneca Pharma India's Return-on-Tangible-Equity has ranged from 9.41 to 24.88. According to the industry distribution chart, AstraZeneca Pharma India ranks #163 out of 897 companies in the Drug Manufacturers industry, placing it in the top 18.2%.
Is AstraZeneca Pharma India's Return-on-Tangible-Equity too high?
AstraZeneca Pharma India's current Return-on-Tangible-Equity of 20.57% is near median its 10-year median of 18.97. Over the past 10 years, this metric has ranged from a low of 9.41 to a high of 24.88. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. AstraZeneca Pharma India's value of 20.57% is 160.4% above this industry median. Based on the distribution chart, AstraZeneca Pharma India ranks #163 out of 897 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, AstraZeneca Pharma India has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca Pharma India's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, AstraZeneca Pharma India ranks #163 out of 897 companies for Return-on-Tangible-Equity. This places AstraZeneca Pharma India in the top 18% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.90. AstraZeneca Pharma India's value of 20.57% is 160.4% above this benchmark. Historically, AstraZeneca Pharma India's own Return-on-Tangible-Equity has ranged from 9.41 to 24.88 over the past decade. While the company's 10-year median is 18.97 vs. the industry median of 7.90, AstraZeneca Pharma India has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 897 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AstraZeneca Pharma India's current Return-on-Tangible-Equity of 20.57% is 160.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on AstraZeneca Pharma India and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AstraZeneca Pharma India's current Return-on-Tangible-Equity is 20.57%, which is near median its own 10-year median of 18.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca Pharma India stock overvalued right now?
Based on GuruFocus' analysis, AstraZeneca Pharma India (NSE:ASTRAZEN) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹10,925.42, compared to a current price of ₹8,310.50 — trading 23.9% below its estimated fair value. The current Return-on-Tangible-Equity is 20.57%, which is near median its 10-year median of 18.97 and 160.4% above the Drug Manufacturers industry median of 7.90. AstraZeneca Pharma India's overall GF Score™ is 94/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For AstraZeneca Pharma India (NSE:ASTRAZEN), the current Return-on-Tangible-Equity is 20.57% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AstraZeneca Pharma India (NSE:ASTRAZEN) Overvalued in 2026?
Based on GuruFocus' analysis, AstraZeneca Pharma India stock appears to be undervalued.
The current stock price of ₹8,310.50 is trading 23.9% below its estimated GF Value™ of ₹10,925.42.
GuruFocus considers AstraZeneca Pharma India to be Modestly Undervalued.
Key valuation signals for NSE:ASTRAZEN:
Return-on-Tangible-Equity: 20.57% (near median its 10-year median of 18.97)
GF Value™: ₹10,925.42 vs. price of ₹8,310.50 (23.9% below fair value)
Industry Position: 160.4% above the Drug Manufacturers median (#163 of 897)
No single metric tells the full story. See the NSE:ASTRAZEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AstraZeneca Pharma India Ltd is engaged in the manufacture, trading, and marketing of pharmaceutical products. Its only operating segment is Healthcare. The company generates revenue from the sale of products such as Tablets, Injectables, and Inhalation. Geographically, it derives a majority of its revenue from India. It focuses on areas such as Cardiovascular, Renal and Metabolism (CVRM), Oncology, Respiratory, Inflammation, Autoimmunity, Neuroscience Infection and Vaccines. The company operates within India, and outside, like Cambridge, Gothenburg, and Gaithersburg. The majority of revenue is from India.
94GF Score
Get the complete analysis for NSE:ASTRAZEN
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ASTRAZEN has been successfully added to your 
